After completing this activity, the participant should be better able to:

• Review the impact of diet and diet quality on cardiometabolic health.
• Describe common elements of healthful eating patterns to promote cardiometabolic health according to evidence-based recommendations and guidelines.
• Discuss physical activity guidelines for patients with chronic health conditions or with cardiometabolic risk factors.
• Discuss the connections between sleep disorders or poor sleep and cardiometabolic health
• Review the clinical presentation of various sleep disorders and their associated treatment options.
• Develop individualized and comprehensive lifestyle approaches to reduce cardiometabolic risk, including incorporating healthful eating patterns, physical activity, smoking cessation advice, and assessment and adequate referral for sleep disorders.

After completing this activity, the participant should be better able to:

• Define obesity as a treatable disease and incorporate practical approaches for its screening and diagnosis.
• Summarize the efficacy and safety of lifestyle interventions and weight loss pharmacotherapy in the treatment of patients with obesity.
• Discuss the efficacy and safety of metabolic surgery in the treatment of obesity, as well as improving cardiometabolic outcomes.
• Review the burden, pathophysiology and impacts of NAFLD and NASH.
• List current and emerging strategies for the screening, diagnosis, and treatment of NAFLD and NASH.
• Develop comprehensive individualized treatment options for patients with obesity that promote and sustain weight loss.

After completing this activity, the participant should be better able to:

• Identify risk factors, as well as screening and diagnostic criteria in order to identify patients with type 2 diabetes or prediabetes in a timely manner.
• Discuss efficacy and safety of medication classes for type 2 diabetes.
• Review current guidelines and evidence-base for the individualization of T2DM therapy.
• List the efficacy and safety of approaches for intensive glycemic management in patients with type 2 diabetes, including continuous glucose monitoring, insulins, and insulin delivery systems.
• Select evidence-based therapy for patients with type 2 diabetes and comorbidities such as ASCVD, HF, or CKD.

After completing this activity, the participant should be better able to:

• Outline strategies for the timely screening and diagnosis of hypertension.
• Review the efficacy and safety of out-of-office vs. in-office blood pressure measurements.
• Explain evidence-based approaches for screening and diagnosing resistant hypertension.
• Summarize the efficacy and safety of pharmacological and non-pharmacological approaches for the treatment of hypertension.
• Develop individualized treatment options for patients with hypertension based on current evidence-base and guideline recommendations.

After completing this activity, the participant should be better able to:

• List current and emerging treatment options for lipid lowering, including for hypercholesterolemia, hypertriglyceridemia, and elevated lipoprotein a.
• Recognize the burden of other lipid players beyond LDL-C in the development of atherosclerosis and residual ASCVD risk.
• Develop individualized treatment options for patients with dyslipidemia based on current treatment options and guideline recommendations.

After completing this activity, the participant should be better able to:

• Summarize the burden, risk factors, and screening criteria for CAD or PAD.
• Review current guidelines for antithrombotic therapy in patients with CAD or PAD.
• Discuss risk factors, symptom presentation, stages and classification of heart failure.
• Review recent advances in HF therapies and clinical guidelines.
• List screening criteria and technological advances for the identification of common arrhythmias.
• Explain current treatment options and guidelines for the prevention and treatment of common arrhythmias, including stroke prevention in patients with arrhythmias.
• Summarize current evidence and guidelines about antithrombotic therapy in patients with a recent ACS event.
• Recognize the significant burden of CVD in women, as well as specific differences in risk factors and symptoms presentation.

After completing this activity, the participant should be better able to:

• Review the pathophysiology, disease burden, and risk factors for CKD.
• Identify patients at risk for CKD based on recommended screening and diagnostic practices.
• Summarize available treatment options for CKD that preserve kidney function and slow CKD progression.

After completing this activity, the participant should be better able to:

• Recognize the need for improved care coordination in the treatment of cardiometabolic patients.
• Outline practical steps and strategies to enhance team-based care, multidisciplinary collaboration, and patient education to improve outcomes for cardiometabolic patients across the care continuum.

After completing this activity, the participant should be better able to:

• Discuss the disproportionate burden of cardiometabolic disease and cardiometabolic risk in racial and ethnic minorities.
• Identify and address clinical, behavioral, and cultural factors that contribute to the increased cardiometabolic burden in racial and ethnic minorities.
• Summarize individualized risk assessment approaches and tailored therapy for treatment of cardiometabolic risk or diseases, including type 2 diabetes, hypertension, dyslipidemia, obesity, and cardiovascular disease, in patients from racial and ethnic minorities.